JP2015518561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518561A5 JP2015518561A5 JP2015501847A JP2015501847A JP2015518561A5 JP 2015518561 A5 JP2015518561 A5 JP 2015518561A5 JP 2015501847 A JP2015501847 A JP 2015501847A JP 2015501847 A JP2015501847 A JP 2015501847A JP 2015518561 A5 JP2015518561 A5 JP 2015518561A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- peptide
- composition
- epha2
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 11
- 108010055196 EphA2 Receptor Proteins 0.000 claims 10
- 210000000130 stem cell Anatomy 0.000 claims 9
- 238000011275 oncology therapy Methods 0.000 claims 8
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 6
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 6
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 108091005601 modified peptides Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000010176 18-FDG-positron emission tomography Methods 0.000 claims 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000012831 peritoneal equilibrium test Methods 0.000 claims 1
- 238000012636 positron electron tomography Methods 0.000 claims 1
- 238000012877 positron emission topography Methods 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612826P | 2012-03-19 | 2012-03-19 | |
| US61/612,826 | 2012-03-19 | ||
| PCT/US2013/032936 WO2013142477A1 (en) | 2012-03-19 | 2013-03-19 | Methods for treating and monitoring the status of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018111785A Division JP2018199675A (ja) | 2012-03-19 | 2018-06-12 | 癌の状態を治療及びモニタリングする方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518561A JP2015518561A (ja) | 2015-07-02 |
| JP2015518561A5 true JP2015518561A5 (enExample) | 2016-05-19 |
| JP6502247B2 JP6502247B2 (ja) | 2019-04-17 |
Family
ID=49223299
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501847A Active JP6502247B2 (ja) | 2012-03-19 | 2013-03-19 | 癌の状態を治療及びモニタリングする方法 |
| JP2018111785A Pending JP2018199675A (ja) | 2012-03-19 | 2018-06-12 | 癌の状態を治療及びモニタリングする方法 |
| JP2020101337A Pending JP2020158518A (ja) | 2012-03-19 | 2020-06-11 | 癌の状態を治療及びモニタリングする方法 |
| JP2021213614A Pending JP2022058444A (ja) | 2012-03-19 | 2021-12-28 | 癌の状態を治療及びモニタリングする方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018111785A Pending JP2018199675A (ja) | 2012-03-19 | 2018-06-12 | 癌の状態を治療及びモニタリングする方法 |
| JP2020101337A Pending JP2020158518A (ja) | 2012-03-19 | 2020-06-11 | 癌の状態を治療及びモニタリングする方法 |
| JP2021213614A Pending JP2022058444A (ja) | 2012-03-19 | 2021-12-28 | 癌の状態を治療及びモニタリングする方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150079135A1 (enExample) |
| EP (4) | EP2828664B1 (enExample) |
| JP (4) | JP6502247B2 (enExample) |
| CA (2) | CA3223380A1 (enExample) |
| ES (3) | ES2887580T3 (enExample) |
| WO (1) | WO2013142477A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| IL302345B2 (en) | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| ES2935702T3 (es) | 2018-04-11 | 2023-03-09 | Enterome S A | Péptidos antigénicos para la prevención y el tratamiento del cáncer |
| WO2019197563A2 (en) * | 2018-04-11 | 2019-10-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE4121547A1 (de) | 1991-06-28 | 1993-01-14 | Daimler Benz Ag | Mehrschichtisolierfolie |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| ATE161190T1 (de) | 1991-10-07 | 1998-01-15 | Biogen Inc | Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| WO2002070007A1 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| AU2002322478A1 (en) | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| FR2838742B1 (fr) * | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| KR20110094361A (ko) | 2003-04-11 | 2011-08-23 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| EP1945754B1 (en) * | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US8343461B2 (en) * | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| US20080118518A1 (en) * | 2006-09-07 | 2008-05-22 | Cirrito Thomas P | Cancer stem cell-targeted cancer therapy |
| CA2698597A1 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Monitoring cancer stem cells |
| AU2008207945A1 (en) * | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
| JP2010190572A (ja) * | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| DK2608799T3 (en) * | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
-
2013
- 2013-03-19 ES ES18189485T patent/ES2887580T3/es active Active
- 2013-03-19 US US14/386,242 patent/US20150079135A1/en not_active Abandoned
- 2013-03-19 ES ES20211725T patent/ES2973957T3/es active Active
- 2013-03-19 EP EP13763504.1A patent/EP2828664B1/en active Active
- 2013-03-19 ES ES13763504T patent/ES2699817T3/es active Active
- 2013-03-19 CA CA3223380A patent/CA3223380A1/en active Pending
- 2013-03-19 JP JP2015501847A patent/JP6502247B2/ja active Active
- 2013-03-19 CA CA2902415A patent/CA2902415C/en active Active
- 2013-03-19 EP EP20211725.5A patent/EP3855184B1/en active Active
- 2013-03-19 EP EP23210443.0A patent/EP4361634A3/en not_active Withdrawn
- 2013-03-19 EP EP18189485.8A patent/EP3431997B1/en active Active
- 2013-03-19 WO PCT/US2013/032936 patent/WO2013142477A1/en not_active Ceased
-
2018
- 2018-02-12 US US15/894,121 patent/US20190031772A1/en not_active Abandoned
- 2018-06-12 JP JP2018111785A patent/JP2018199675A/ja active Pending
-
2020
- 2020-06-11 JP JP2020101337A patent/JP2020158518A/ja active Pending
-
2021
- 2021-12-28 JP JP2021213614A patent/JP2022058444A/ja active Pending
-
2022
- 2022-08-04 US US17/881,007 patent/US20230374152A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jones et al. | Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica | |
| JP2015518561A5 (enExample) | ||
| Tan et al. | Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes | |
| JP2012041338A5 (enExample) | ||
| JP2006516116A5 (enExample) | ||
| TWI748957B (zh) | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 | |
| JP6955324B2 (ja) | 医薬化合物を評価するための新規動物モデル | |
| US20160317635A1 (en) | Multivalent Breast Cancer Vaccine | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| Nikitin et al. | Assessment of structurally modified plant virus as a novel adjuvant in toxicity studies | |
| AU2019264673A1 (en) | Vaccine compositions and methods for restoring NKG2D pathway function against cancers | |
| Daoud et al. | Changes of T-helper type 1/2 cell balance by anticholinergic treatment in allergic mice | |
| Yuan et al. | Therapeutic role of a vaccine targeting RANKL and TNF-α on collagen-induced arthritis | |
| Qian et al. | Immunogenicity and protective efficacy of a recombinant Lactococcus lactis vaccine against HSV-1 infection | |
| Cash et al. | GSK249320, a monoclonal antibody against the axon outgrowth inhibition molecule myelin-associated glycoprotein, improves outcome of rodents with experimental stroke | |
| US20200046818A1 (en) | Yeast-based immunotherapy for chordoma | |
| WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| Li et al. | Effects of a 15-amino-acid isoform of amyloid-β expressed by silkworm pupae on B6C3-Tg Alzheimer’s disease transgenic mice | |
| Zhang et al. | Multiple antigenic polypeptide composed of heparanase B-cell epitopes shrinks human hepatocellular carcinoma in mice | |
| CN105330749A (zh) | 放疗增敏融合多肽的构建及应用 | |
| JP2018500882A5 (enExample) | ||
| US20220228128A1 (en) | Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy | |
| Symchych et al. | Anticancer effectiveness of vaccination based on xenogeneic embryo proteins applied in different schedules | |
| Wu et al. | Role of high central leptin activity in a scoliosis model created in bipedal amputated mice | |
| HK40058749A (en) | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |